Philadelphia, PA (July 1, 2019) – Oncoceutics, Inc. announced a scientific publication in the journal Leukemiademonstrating selective and potent agonism of the G-protein coupled receptor (GPCR) GPR132 by ONC212, an imipridone derivative of ONC201. GPR132 is an orphan GPCR previously shown to play a tumor suppressor role in acute leukemias that has not been targeted
Philadelphia, PA (June 4, 2019) – Oncoceutics, Inc. announced a publication in the Journal for ImmunoTherapy of Cancer demonstrating ONC201 immunostimulatory activity in advanced cancer patients when given the recommended phase II dose (RP2D) of 625 mg orally every one week. The publication, which describes a Phase I trial conducted by Mark Stein, MD, at
Philadelphia, PA (May 17, 2019) – Oncoceutics, Inc. announced that the latest efficacy data for the use of ONC201 in adult recurrent H3 K27M-mutant glioma will be presented in an Oral Abstract Session at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. In addition, there will be an update
Philadelphia, PA (May 13, 2019) – Oncoceutics announced today that Michael Chiarella, an industry veteran with more than 20 years’ experience at a number of large and small biotech companies, is joining the company as Vice President, Clinical Operations. Mr. Chiarella will be responsible for building out Oncoceutics’ clinical operations in connection with the company’s
Business Development